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The fundamental role of Na,K-ATPase in eukaryotic cells calls for complex and efficient
regulation of its activity. Besides alterations in gene expression and trafficking, kinetic
properties of the pump are modulated by reversible association with single span
membrane proteins, the FXYDs. Seven members of the family are expressed in
a tissue-specific manner, affecting pump kinetics in all possible permutations. This
mini-review focuses on functional properties of FXYD2 studied in transfected cells, and on
noteworthy and unexpected phenotypes discovered in a Fxyd2−/− mouse. FXYD2, the
gamma subunit, reduces activity of Na,K-ATPase either by decreasing affinity for Na+, or
reducing Vmax. FXYD2 mRNA splicing and editing provide another layer for regulation of
Na,K-ATPase. In kidney of knockouts, there was elevated activity for Na,K-ATPase and
for NCC and NKCC2 apical sodium transporters. That should lead to sodium retention
and hypertension, however, the mice were in sodium balance and normotensive. Adult
Fxyd2−/− mice also exhibited a mild pancreatic phenotype with enhanced glucose
tolerance, elevation of circulating insulin, but no insulin resistance. There was an increase
in beta cell proliferation and beta cell mass that correlated with activation of the PI3K-Akt
pathway. The Fxyd2−/− mice are thus in a highly desirable state: the animals are resistant
to Na+ retention, and showed improved glucose control, i.e., they display favorable
metabolic adaptations to protect against development of salt-sensitive hypertension and
diabetes. Investigation of the mechanisms of these adaptations in the mouse has the
potential to unveil a novel therapeutic FXYD2-dependent strategy.
Keywords: gamma subunit, knockout mouse, renal sodium transporters, hypertension, adaptation, pancreatic
islets, beta cells
REGULATORY SUBUNITS OF NA,K-ATPASE
FXYDs are established regulators of Na,K-ATPase (Garty and Karlish, 2005; Geering, 2006). This
is a family of seven small single span membrane proteins (FXYD1-FXYD7) with differential
and actively regulated expression in tissues and cells (Sweadner and Rael, 2000; Geering, 2006;
Figure 1A). Association of each with Na,K-ATPase leads to modulation of activity of the enzyme in
all possible ways: inhibition or activation of Vmax, and increase or decrease of affinity for Na
+,
K+, or ATP. A remarkable feature of FXYD proteins is their interchangeability, which allows
fine-tuning of kinetic properties of the Na,K-ATPase in order to adjust to any given physiological or
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FIGURE 1 | Functions of FXYDs and the tissue distribution of FXYD2.
(A) Schematic representation of how FXYD proteins alter functions of
Na,K-ATPase. Effects on affinities for substrates are well-characterized. How
FXYD proteins function at the molecular level for the demonstrated alterations
of signaling pathways has yet to be determined. (B) Expression sites of FXYD2
in rodents. The principal sites are renal tubules, pancreatic beta cells, and
sensory neurons. Mammary glands may also express FXYD2, but this remains
to be systematically investigated.
pathological situation (Arystarkhova et al., 2007). Based on
crystal structures of Na,K-ATPase, the FXYD subunit is
positioned on the periphery of the complex (Toyoshima et al.,
2011), which may be a structural basis for “easy” exchange
of regulatory subunits. Association of FXYD proteins with
alpha/beta complex occurs post-translationally either in Golgi or
even at the plasma membrane (Crambert et al., 2002; Pihakaski-
Maunsbach et al., 2008; Moshitzky et al., 2012). This may
facilitate exchange of regulatory subunits within an already-
functioning complex.
FXYD2 protein was the first member of the family associated
with Na,K-ATPase: it was identified as a proteolipid labeled
with a photosensitive-derivative of ouabain, specific inhibitor
of Na,K-ATPase, along with the alpha and beta subunits
(Forbush et al., 1978). Further analysis of the “gamma subunit”
(FXYD2) confirmed its intimate relation to Na,K-ATPase by co-
localization and co-immunoprecipitation with the alpha subunit
from kidney membranes (Mercer et al., 1993). Distribution of
FXYD2 (at least in rodent) is quite limited: it is highly expressed
in kidney with lower representation in pancreas and even lower
in mammary gland (Sweadner et al., 2000) and dorsal root
ganglia (Venteo et al., 2012; Wang et al., 2015; Figure 1B).
FXYD2 stands out from the family by being present in two splice
variants: FXYD2a and FXYD2b, that differ only at the small
N-terminal segment exposed on the extracellular side (Küster
et al., 2000; Sweadner et al., 2000; Arystarkhova et al., 2002b).
The distribution patterns of the FXYD2 splice variants in kidney
are not identical (Pu et al., 2001; Arystarkhova et al., 2002b). Co-
expression of FXYD2a and FXYD2b is seen in medullary thick
ascending limb. Proximal convoluted tubules however, express
only FXYD2a, while only FXYD2b is found in distal convoluted
tubules and connecting tubules. The data suggest engagement of
the distinct segments of FXYD2a and FXYD2b in extracellular
association with tubule-specific partners that are not identified
yet. It should be noted that association with multiple partners
has been described for other FXYD proteins, such as FXYD1
with Na+/Ca2+ exchanger (Wang et al., 2006) or L-type Ca2+
channel (Guo et al., 2010), and FXYD4 with KCNQ1 K+ channel
(Jespersen et al., 2006).
FXYDs can also influence cell growth through downstream
signaling pathways. FXYD3 and FXYD5 (dysadherin) are
expressed in some normal tissues but are elevated in some types
of cancer (Arimochi et al., 2007; Nam et al., 2007). We have
demonstrated that FXYD2 decreases cell growth rates in culture
(Arystarkhova et al., 1999, 2002a, 2007; Wetzel et al., 2004), while
FXYD3 has been demonstrated to increase growth rates (Kayed
et al., 2006). This is yet another example of the multiplicity of
ways that different FXYDs can act.
FUNCTIONAL PROPERTIES OF FXYD2
LEARNED FROM TRANSFECTED CELLS
Remarkably, no endogenously expressed FXYD2 protein is found
in any renal mammalian cell line (Arystarkhova et al., 2007);
this is also true of a pancreatic beta cell line (Arystarkhova
et al., 2013). Functional assessment of FXYD2 has been
explored in expression systems. Reduction of the affinity
for Na+ is the most widely-supported effect of FXYD2
(Béguin et al., 1997; Arystarkhova et al., 1999; Therien et al.,
1999). Notably, both splice variants, FXYD2a and FXYD2b,
similarly inhibited Na,K-ATPase by decreasing apparent affinity
for Na+ (Arystarkhova et al., 2002a). This rules out the
N-terminal splice variants for modulation of this kinetic
parameter. Further structure-function studies implicated the
transmembrane segment of FXYD proteins in the control of Na+
affinity (Lindzen et al., 2003).
Unexpectedly though, an unidentified post-translational
modification relieved FXYD2a-mediated reduction of apparent
Na+ affinity in stably-transfected cells (Arystarkhova et al.,
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2002a). Post-translational modification is a common theme
in the FXYD family: phosphorylation (Silverman et al., 2005;
Fuller et al., 2009), palmitoylation (Tulloch et al., 2011), O-
glycosylation (Tsuiji et al., 2003; Crambert et al., 2004), and
S-glutathionylation (Bibert et al., 2011) have all been reported
for various FXYDs. The palmitoylation and S-glutathionylation
entail modification of one or both cysteine residues immediately
following the transmembrane span. Palmitoylation was required
for Na,K-ATPase inhibition by FXYD1 (Tulloch et al., 2011),
while S-glutathionylation of FXYD1 correlated with reduction
of inhibition mediated by S-glutathionylation of the β1
subunit (Bibert et al., 2011). FXYD2 is not susceptible to
S-glutathionylation (Bibert et al., 2011), but in silico analysis
of FXYD2a structure predicts Cys52 (FXYD2a numbering) as a
potential site for palmitoylation (Tulloch et al., 2011). However,
whether FXYD2 is indeed palmitoylated and whether this kind of
regulation takes place in vivo awaits further investigation.
In addition to mRNA splicing and post-translational
modifications, we observed that mRNA for FXYD2b could
be selectively edited, at least in transfected cells (Sweadner
et al., 2011). Single base substitution C172U of the RNA
results in introduction of a premature in-frame stop codon.
The truncated protein was retained intracellularly due to
exposure of an ER retrieval signal, -KKXX. The RNA editing
was observed in several established cell lines of different origin
(NRK-52E renal epithelial cells, C6 glioma, and L6 myotubes)
thus generalizing the phenomenon. Functionally, expression
of the truncated form of FXYD2b completely abrogated the
reduction of apparent Na+ affinity of Na,K-ATPase activity.
Cells expressing truncated FXYD2b also exhibited no growth
delay as opposed to transfectants with full length FXYD2b.
Remarkably, no truncation was found for FXYD2a, suggesting
selective post-transcriptional control of FXYD2b. This is a
potential indirect mechanism for differential regulation of Na+
affinity by the splice forms. Whether the modification of the
transcript plays a protective role, ensuring that FXYD2b is
inactive even if made in cells where it may be deleterious, or
the truncated protein has another biological role, remains to be
discovered.
FXYD2a was upregulated in cells by several types of cellular
stress, including hyperosmotic and oxidative (Wetzel et al.,
2004). In these conditions it reduced the Vmax of the enzyme.
The stress-related response was observed in cells of different
origins, indicating a general cell response via a signaling
process linked to the primary insult. In parallel to inhibition
of Na,K-ATPase activity, expression of FXYD2 (either by
transfection or induction) correlated with a reduction in rate of
cell growth (Wetzel et al., 2004). An escape from cell growth delay
was achieved by selective siRNA silencing of FXYD2 during on-
going stress, suggesting the adaptive value of FXYD2 as a general
cellular mechanism of regulation of cell growth.
Taken together, FXYD2 can be considered an endogenous
inhibitory subunit of Na,K-ATPase affecting the pump’s activity
via reduction of affinity for Na+ and Vmax. The control occurs
at multiple levels, such as alternative splicing, post-translational
modification, and mRNA editing. The FXYD proteins evidently
also participate in fine-tuning the signaling role of Na,K-ATPase.
FUNCTIONAL PROPERTIES OF FXYD2
LEARNED FROM KNOCKOUT MICE
Generation of knockout mice was an essential step toward
characterization of FXYD2. Global knockout of FXYD2 was
performed via replacement of the transmembrane domain coding
sequence with a LacZ cassette with a selectable marker (Jones
et al., 2005). The higher Na+ affinity in assays of kidney
membranes from Fxyd2−/− knockout mice confirmed that
FXYD2 normally reduces the Na+ affinity of Na,K-ATPase, thus
complementing studies from transfected cells. The observed
changes were in a physiological range suitable for modulation
of Na,K-ATPase by hormones. No significant variation of K+
affinity or reduction in the affinity for ATP was observed between
in Fxyd2−/− and WT, suggesting that alterations observed
earlier in different expression systems (Therien et al., 1999;
Arystarkhova et al., 2002a; Pu et al., 2002) might be cell specific.
FXYD2−/− MICE HAVE A PANCREATIC
PHENOTYPE
Although viable and fertile, the knockout mice had obvious
problems with reproduction: reduced apparent conception
rate, smaller surviving litter size, and reduced percentage of
successful litters in pairs with Fxyd2−/− or even Fxyd2+/− dams
(Arystarkhova et al., 2013). Thus deletion or even dose reduction
of the Fxyd2 gene was unfavorable for female reproduction.
However, if pups survived the perinatal period (0–3 days),
knockout mice lived a normal life-span with growth parameters
not much different from wild type mice.
A renal phenotype was expected since kidney has the highest
level of expression of FXYD2 (Arystarkhova et al., 2002a;
Wetzel et al., 2004). However, initial analysis did not reveal
any significant impairment in renal function in Fxyd2−/− mice
kept under optimal care. Instead, a reduced blood glucose
level was seen in Fxyd2−/− mice either under fed or fasted
conditions (Arystarkhova et al., 2013). Although this could
indicate peripheral resistance to insulin, either young or mature
Fxyd2−/− mice revealed insulin sensitivity indistinguishable
from their wild type controls. Remarkably, there was a dramatic
improvement in glucose tolerance in the knockout animals. All
of the above imply a metabolic phenotype of low blood glucose
in Fxyd2−/− mice. Reduction in blood glucose correlated with
an elevation in circulating insulin (2–2.5 fold) either under
basal or glucose-stimulated conditions (Arystarkhova et al.,
2013). Elevated insulin was sustained in pregnant Fxyd2−/−
and Fxyd2+/− dams close to delivery (E18–E20) consistent with
maternal pathophysiology as the reason for the fragility and
low survival rate of newborn pups, by affecting either milk
production or nurturing behavior.
Based on GEO profiles, pancreas is the second tissue (after
kidney) in abundance of FXYD2 expression. By RT-PCR and
Western blots, both splice variants of FXYD2 were identified
in pancreatic islets from rodent and human tissues (Flamez
et al., 2010). Immunofluorescence, however, revealed unusual
localization of the protein considering its role as a regulatory
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subunit of Na,K-ATPase. While some of the FXYD2 was found
at the plasma membrane (together with Na,K-ATPase), most
FXYD2 was observed in the cytoplasm (Flamez et al., 2010;
Arystarkhova et al., 2013). Whether the apparent separation
of FXYD2 from Na,K-ATPase indicates intracellular trafficking
of FXYD2 within beta cells in response to yet an unidentified
physiological stimulus requires further investigation. We did
not detect the edited mRNA product by RT-PCR. In pancreas
FXYD2 may play a biological role distinct from regulation of
Na,K-ATPase, and the molecular mechanism of intracellular
retention may be interaction with another protein.
Functionally, there was no significant difference in ability
to secret insulin from freshly isolated pancreatic islets from
WT and Fxyd2−/− mice (Arystarkhova et al., 2013). However,
morphometric analysis revealed a higher number of insulin-
producing beta cells per islet cross-sectional area in the knockout
mice compared to WT. This led to an increase in total beta
cell mass/pancreas from the Fxyd2−/− knockouts (Arystarkhova
et al., 2013). Thus depletion of FXYD2 from pancreatic islets
apparently increases the rate of cell division, consistent with
the effect of FXYD2 on growth rate in transfected cells in
culture. Beta cell hyperplasiamay underlie the elevation of insulin
production that in turn may explain the observed phenotype of
low blood glucose. Nomorphological changes were seen in acinar
cells from Fxyd2−/− mice, implying preferential hyperplasia
of the endocrine islet compartment. It should be noted that
enhanced proliferation of beta cells in Fxyd2−/− mice stayed
within the physiological range, i.e., unlike insulinomas. All
together the data suggest that removal of FXYD2 is beneficial for
pancreatic beta cells.
On the molecular level, freshly isolated islets from Fxyd2−/−
mice exhibited significantly higher levels of phosphorylation
of Akt (PKB; Arystarkhova et al., 2013), one of the central
players in regulation of beta cell mass and function (Bernal-
Mizrachi et al., 2001; Blandion-Rosano et al., 2012). This
may underlie the islet hyperplasia observed in Fxyd2−/−
mice, and reflect ongoing signaling in adults. Experimentally,
inducible expression of FXYD2 in rat INS 832/13 cells was
paralleled by a reduction in phosphorylation of Akt, whereas
time-dependent degradation of FXYD2 resulted in its gradual
elevation (Arystarkhova et al., 2013). PI3 kinase is the upstream
activator of Akt kinase, and it had been shown to interact with
Na,K-ATPase (Yudowski et al., 2000). A potential scenario is
that depletion of FXYD2 leads to a conformational change in
Na,K-ATPase and, as a result, sustained activation of PI3K,
leading to enhanced activity of Akt. This would implicate
FXYD2 as an upstream player in the Akt signaling pathway
in pancreatic beta cells. Activation of Akt is one of the
important links between growth signals and regulation of β
-cell expansion (Bernal-Mizrachi et al., 2001; Elghazi et al.,
2007). Downstream targets of Akt, tuberous sclerosis complex 1
and 2 (TSC1/2) and mechanistic target of rapamycin complex
1 (mTORC1), are prime candidates for enhancing cell cycle
progression (Blandino-Rosano et al., 2012). The hope is that
further investigation of FXYD2 will lead to novel regulators
of beta cell mass to enhance insulin secretion for therapeutic
purposes.
USEFUL ADAPTATIONS TO FXYD2
DEPLETION FROM KIDNEY
Na,K-ATPase is located in basolateral membranes in renal
tubules where it generates the driving force for Na+ entry across
the apical membrane. Theoretically deletion of the inhibitory
subunit FXYD2 should enhance renal Na+ reabsorption by
increasing both Na+ affinity and Vmax of Na,K-ATPase in
the proximal tubule. Measured renal Na,K-ATPase activity in
cortical membranes from the knockout mice was elevated
as predicted (Arystarkhova et al., 2014), and so a renal
phenotype was expected. Under basal conditions no significant
differences between WT and knockout mouse were found in
plasma concentration of Na+ or in plasma osmolality, implying
no increase in sodium retention (Jones et al., 2005). Urine
electrolytes (mg/mg creatinine) remained within the normal
range in FXYD2-deficient mice (Jones et al., 2005). In addition,
FXYD2-deficient mice were normotensive and demonstrated
sodium balance indistinguishable from their littermate controls
(Arystarkhova et al., 2014). Taken together, the experimental data
imply that NaCl uptake or eﬄux in appropriate renal segments is
adaptively controlled in the Fxyd2−/− mice.
Regulation of inflow through apical Na+ transporters is
one possibility. Distal convoluted tubule (DCT) and thick
ascending limb (TAL) are the segments with the highest
level of expression of both Na,K-ATPase and FXYD2. The
major apical Na+ transporters there are sodium/chloride
cotransporter (NCC; Subramanya and Ellison, 2014) and
sodium/potassium/chloride cotransporter (NKCC2; Ares et al.,
2011) in DCT and cortical TAL (cTAL), respectively. Both
belong to a family of electroneutral cation-coupled chloride co-
transporters. Functionally, both transporters face the lumen of
the tubules and perform uptake of Na+ from the tubular fluid
driven by the sodium gradient created by Na,K-ATPase. Activity
of both transporters is regulated by expression, trafficking and
phosphorylation. In humans, reduced activity of NKCC2 leads to
severe salt and volume loss and decreased blood pressure (Bartter
syndrome), while reduction in NCC function is associated with
salt wasting and low blood pressure (Gitelman syndrome). In
contrast, gain of function of either transporter is associated
with an increase of Na+ reabsorption and development of salt-
sensitive hypertension (Ares et al., 2011; Hoorn et al., 2011).
If either TAL or DCT were involved in compensation of
Na+ balance in the Fxyd2−/− mice, luminal sodium uptake
should be reduced in those segments, i.e., activity of NKCC2 or
NCC transporters should be diminished. Surprisingly, there was
significant up-regulation of NCC protein expression (by 30%)
and highly augmented phosphorylation of both cortical NKCC2
(at least two-fold) and NCC (4–6 fold at two phosphorylation
sites, pT53 and pS71; Arystarkhova et al., 2014). The level of
phosphorylation of both transporters is usually taken as a proxy
of their activity. Thus high phosphorylation of NCC and NKCC2
in Fxyd2−/− mice would predict even higher Na+ reabsorption
in cTAL and DCT that should eventually lead to hypertension.
In practice, Fxyd2−/− mice revealed no significant difference
in mean arterial pressure (either males or females) under
basal conditions when compared to their wild type littermates
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(Arystarkhova et al., 2014). Thus the compensated physiology
of the mouse and lack of Na+ retention cannot be explained by
downregulation of apical Na+ entry in TAL and DCT segments.
Acute saline challenge of WT and Fxyd2−/− mice also did not
reveal a difference in rate of Na+ excretion between genotypes
(Arystarkhova et al., 2014). Therefore activation of both cortical
NKCC2 and NCC must be explained by compensation in either
more distal or more proximal segments in the knockout mice.
No difference was seen in the expression level or activity of the
distally-expressed amiloride sensitive epithelial sodium channel,
ENaC (Arystarkhova et al., 2014), ruling it out for compensation
for an increase in Na,K-ATPase activity, and leaving proximal
tubules as a likely site of Na+ absorption adjustments in the Fxyd2
knockout mouse.
A testable hypothesis is that increase in activity of Na,K-
ATPase in proximal tubule, the principal site of Na+ reabsorption
from filtrate, would cause excess reabsorption of Na+ into
interstitial spaces and lead to activation of the intrarenal
dopamine response (Aperia, 2000; Carey and Padia, 2013).
This reduces the activity of apical NHE3 transporter, which is
thought to be rate-limiting for Na+ reabsorption (McDonough,
2010), by trafficking it toward the base of the apical villi (Chen
et al., 2009; McDonough, 2010), and internalizes Na,K-ATPase
as well (Pedemonte et al., 2005; Gildea et al., 2009). The Na+
concentration in the lumen in proximal tubules would then
stay high, and the observed hyperstimulation of the downstream
NKCC2 and NCC transporters would be adaptive, bringing the
FXYD2 knockout mouse into Na+ balance.
CONCLUSIONS
To summarize, Fxyd2−/− mice are in a desirable state
when considering the risk factors of metabolic syndrome.
The animals are resistant to elevation of glucose in blood
as well as to Na+ retention, i.e., they display features
unfavorable for development of diabetes or salt-sensitive
hypertension. In addition, deletion of FXYD2 from dorsal
root ganglion neurons correlated with a marked reduction in
a nociceptive adaptation (allodynia) to inflammation (Wang
et al., 2015). Is there a common trait in these beneficial
phenotypes observed in different tissues? We showed that
FXYD2 modulates both ion transport (Arystarkhova et al., 1999,
2002a) and signaling (Arystarkhova et al., 2013). Investigation
of mechanism(s) underlying favorable metabolic adaptations
in the knockout mouse will be a challenge for the coming
years.
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